🏛️ Verified NIH Record • Updated 2026-04-08
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (NCT05446298)
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: OncoC4, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Who can join: Review the eligibility criteria below.
Location: Cancer Treatment Centers of America, Phoenix. 403 — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Cancer Treatment Centers of America, Phoenix. 403 — Goodyear, Arizona
- Honor Health, USOR, 406 — Phoenix, Arizona
- Nuvance Health System, 401 — Danbury, Connecticut
- Baptist MD Anderson Cancer Center, 404 — Jacksonville, Florida
- Sudarshan Sharma, MD. LTD. 414 — Hinsdale, Illinois
- Cancer Treatment Centers of America, Chicago. 410 — Zion, Illinois
- Northwest Cancer Centers - Dyer, IN - USOR, 422 — Dyer, Indiana
- Baptist Health Lexington, 407 — Lexington, Kentucky
- Norton Cancer Institute - St. Matthews, 416 — Louisville, Kentucky
- Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409 — Shreveport, Louisiana
- Minnesota Oncology Hematology, P. A. - USOR, 421 — Maplewood, Minnesota
- Center of Hope, 413 — Reno, Nevada
- The Valley Hosptial, Inc. 411 — Ridgewood, New Jersey
- Women's Cancer Care Associates, LLC. 405 — Albany, New York
- The Ohio State University James Cancer Center, 412 — Columbus, Ohio
- Oncology Associates of Oregon, P. C. - USOR. 419 — Eugene, Oregon
- Texas Oncology, P. A. - Austin, USOR. 417 — Austin, Texas
- Texas Oncology, P.A., Fort Worth - USOR. 420 — Fort Worth, Texas
- Texas Oncology, P. A. Woodlands - USOR, 418 — The Woodlands, Texas
- Texas Oncology - Northeast Texas - USOR, 423 — Tyler, Texas
- Medical College of Wisconsin, 408 — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.